PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1733
- Registration Number
- NCT02791230
- Locations
- 🇺🇸
Boston Medical Center Investigational Pharmacy, Boston, Massachusetts, United States
🇺🇸Northwestern Medical Group, Chicago, Illinois, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment
- Conditions
- Metastatic Renal Cell Carcinoma
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 111
- Registration Number
- NCT02789137
- Locations
- 🇪🇸
Complejo Hospitalario de León, León, Spain
🇪🇸Hospital Arquitecto Marcide de Ferrol, Ferrol, A Coruña, Spain
🇪🇸Hospital Asil de Granollers, Granollers, Barcelona, Spain
A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects
- First Posted Date
- 2016-05-30
- Last Posted Date
- 2018-12-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT02785770
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2019-05-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 269
- Registration Number
- NCT02780167
- Locations
- 🇺🇸
The Dermatology Group, P.C, Verona, New Jersey, United States
🇺🇸Dawes Fretzin Dermatology Group, LLC, Indianapolis, Indiana, United States
🇺🇸Clinical Research Consortium, Las Vegas, Nevada, United States
Topical Multiple Ascending Dose Study for PF-06423264
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 65
- Registration Number
- NCT02778477
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
- Conditions
- Renal Cell Carcinoma
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1349
- Registration Number
- NCT02776644
A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)
- Conditions
- Neutropenia (Low White Blood Cell Count)
- Interventions
- Biological: Filgrastim Hospira (US)Biological: U.S.-approved Neupogen®
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT02766634
- Locations
- 🇺🇸
SeaView Research, Inc., Miami, Florida, United States
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859
- Conditions
- Healthy
- Interventions
- Biological: PF-06823859Drug: Placebo injection SC/IV
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 62
- Registration Number
- NCT02766621
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)
- Conditions
- Neutropenia (Low White Blood Cell Count)
- Interventions
- Biological: Filgrastim Hospira (US)Biological: US-approved Neupogen®
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2016-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT02766647
- Locations
- 🇺🇸
SeaView Research, Inc, Miami, Florida, United States
The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2016-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT02767089
- Locations
- 🇺🇸
Jasper Clinic, Inc., Kalamazoo, Michigan, United States